Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target

Piper Sandler analyst David Amsellem has reiterated an Overweight rating on Axsome Therapeutics (NASDAQ: AXSM) and maintained a price target of $258 for the stock. This endorsement suggests a positive outlook for the company's performance in the market.